Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Figure 2

Proportion of subjects requiring gout flare treatment. Solid lines, open symbols, prior participation in long-term open-label ULT extension trials [13, 14]. Dashed lines and closed symbols, no prior participation in long-term open-label ULT extension trials; squares, febuxostat 40 mg daily; circles, febuxostat 80 mg daily; triangles, allopurinol 200/300 mg daily.

Back to article page